Precision treatment in advanced hepatocellular carcinoma

Topics

Liver cancer · advanced hepatocellular carcinoma · Precision cancer care · Precision medicine · Targeted therapy · Biomarker · Molecular target · sorafenib · lenvatinib · regorafenib · cabozantinib · ramucirumab · Immune checkpoint inhibition · atezolizumab · bevacizumab · nivolumab · pembrolizumab · tremelimumab · durvalumab · VEGF pathway · PD-1/PD-L1 pathway · CTLA-4 · Tumor microenvironment · Genomic profiling · next-generation sequencing · Tumor mutational burden · microsatellite instability · TERT promoter mutations · TP53 mutations · CTNNB1 mutation · ARID1A · MET amplification · FGF19 amplification · FGFR inhibition · HER2 amplification · RAS/MAPK pathway · Wnt/β-catenin pathway · PI3K/AKT/mTOR pathway · alpha-fetoprotein · Barcelona Clinic Liver Cancer staging · Cirrhosis · hepatitis B virus · hepatitis C virus · systemic therapy · combination immunotherapy · Biomarker-driven clinical trial · patient selection · Acquired drug resistance · transcriptomic subtypes · multi-kinase inhibitors · angiogenesis inhibition